TABLE 1.
Baseline Characteristics at SO Therapy Initiation
| Baseline Characteristic | Study Cohort (n=258) |
|---|---|
| Age, years | 50.6 ± 13.9 |
| Dialysis vintage, months | 29.3 ± 27.5 |
| BMI, kg/m2 | 30.4 ± 8 |
| Male, n(%) | 143 (55.4) |
| Race, n(%) | |
| White | 160 (62.0) |
| African American | 64 (24.8) |
| Other | 34 (13.2) |
| Diabetes, n(%) | 121 (46.9) |
| Primary cause of ESRD, n (%) | |
| Diabetes mellitus | 90 (34.9) |
| Hypertension | 69 (26.7) |
| Glomerulonephritis | 47 (18.2) |
| Polycystic kidney disease | 10 (3.9) |
| Other | 34 (13.2) |
| Unknown | 8 (3.1) |
| Baseline PB dispensed through FreseniusRx | |
| No PB recorded | 166 (64.3) |
| PB recorded in the FKC EHR database | 110 (66.3) |
| PB recorded | 92 (35.7) |
| Calcium acetate | 19 (20.7) |
| Lanthanum carbonate | 5 (5.4) |
| Sevelamer | 58 (63.0) |
| >1 PB recorded | 10 (10.8) |
| PD modality | |
| Manual (CAPD) | 34 (13.2) |
| Automated (CCPD) | 196 (76) |
| Switched (CAPD to CCPD) | 28 (10.8) |
| Clinical parameters | |
| Serum phosphorus (mg/dL) | 6.5 ± 1.4 |
| Albumin-corrected calcium (mg/dL) | 9.4 ± 0.7 |
| Intact PTH (pg/mL) | 459 ± 317 |
| Serum albumin (g/dL) | 3.7 ± 0.4 |
| Kru (mL/min/1.73 m2) | 2.72 ± 2.45 |
| PD Kt/V | 1.7 ± 0.4 |
| Total Kt/V | 2.2 ± 0.5 |
Values are expressed as mean ± standard deviation, or n (%)
Abbreviations: BMI - body mass index (kg/m2); CAPD - continuous ambulatory PD; CCPD - continuous cycling PD; Kru - residual urea clearance; FKC EHR – Fresenius Kidney Care electronic health records; PB – phosphate binder; PD – peritoneal dialysis; PTH – parathyroid hormone